<DOC>
	<DOCNO>NCT00148837</DOCNO>
	<brief_summary>Viral hepatitis C prognosis relate presence fibrosis risk develop cirrhosis hepatic cancer . The study evaluate efficacy prazosin make hepatic fibrosis regress , patient chronic hepatitis C severe fibrosis .</brief_summary>
	<brief_title>Efficacy Prazosin Versus Placebo Associated With Peg-Interferon Alpha 2b Ribavirin Chronic Hepatitis C With Genotype 1 4 Severe Fibrosis</brief_title>
	<detailed_description>Treatment hepatitis C interferon ribavirin virological effect . Viral hepatitis C prognosis relate presence fibrosis risk develop cirrhosis hepatic cancer . In vitro study prazosin suggest effect hepatic fibrosis , clinical effect prazosin hepatic fibrosis induce hepatitis C infection unknown . The purpose multicentric national study compare effect among hepatic fibrosis peg-interferon alpha 2b ribavirin prazosin ( placebo ) . 112 patient viral hepatitis C , genotype 1 4 , severe fibrosis , randomly assign one two treatment group : peg-interferon alpha 2b ribavirin , prazosin placebo . Peg-interferon alpha 2b administer week ( 1.5 micro g per kg ) 48 week , ribavirin 1,000 1,200 mg per day ( accord weight ) 48 week , prazosin/placebo 5 mg ( 2 pill ) per day 96 week . Evaluation do 96 week . The primary end-point proportion patient present decrease fibrosis . Secondary end-points criterion histological response , virological response , biochemical response .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2b</mesh_term>
	<mesh_term>Prazosin</mesh_term>
	<criteria>Chronic viral hepatitis C , genotype 1 4 Fibrosis F3 F3F4 , assess score Metavir system Initial treatment HCV Psychiatric pathology Alcool consummation Pregnancy plan pregnancy Breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>Hepatitis C , Chronic</keyword>
	<keyword>Fibrosis</keyword>
	<keyword>Interferon Alfa-2b</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Prazosin</keyword>
</DOC>